Dexcom Appoints Former Stryker CFO Glenn Boehnlein to Board of Directors

Executive & Board Changes Summary

On September 10, 2026, DexCom, Inc. ($DXCM) filed a Form 8-K announcing the expansion of its Board of Directors to 13 members and the appointment of Glenn S. Boehnlein as a new independent director, effective immediately.

Key Details of the Appointment:

• Term: Mr. Boehnlein will serve for a term expiring at the 2027 annual meeting of stockholders.
• Committee Assignments: Appointed to serve on both the Audit Committee and the Operations & Innovation Committee.
• Director Independence: The Board determined Mr. Boehnlein qualifies as an independent director under Nasdaq listing standards and SEC regulations.
• Background: Mr. Boehnlein spent over two decades in medical technology leadership, most notably serving as VP and Chief Financial Officer of Stryker Corporation from 2016 to 2025. He also serves on the boards of Inogen, Inc. and Agilent Technologies, Inc.

Compensation & Equity Grants:

• Initial Appointment Grant: Received an initial grant of Restricted Stock Units (RSUs) with an aggregate fair value of $500,000, vesting annually over three years subject to continued service.
• Annual Equity Compensation: Eligible to receive standard non-employee director annual equity grants starting at the 2027 Annual Meeting, valued at approximately $347,500 in RSUs for board and committee service.
• Acceleration: Full acceleration of outstanding director equity awards upon a change in control.